TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01948349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue scraping
Description: Two of four groups will use tongue scraping in conjunction with a normal oral hygiene protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue scraping
Description: Two of four groups will use tongue scraping in conjunction with a normal oral hygiene protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bracket design
Description: Two groups will be allocated to have self-ligating (Carriere) brackets. The other two groups will receive standard twin brackets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bracket design
Description: Two groups will be allocated to have self-ligating (Carriere) brackets. The other two groups will receive standard twin brackets.
Study: NCT00899600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
Study: NCT00784706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EP
Description: Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIT
Description: The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIT
Description: The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
Study: NCT01231828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: L-carnitine 4g per day (4 bottles of 10ml).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Lactulose (30-60 ml per day)
Study: NCT01010061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
Study: NCT03860662

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nociceptor flexor reflex
Description: The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
Study: NCT03243955

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Verum TEAS
Description: TENS unit with electrodes applied to acupuncture point locations

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TEAS
Description: TENS unit with electrodes applied to non-acupuncture point locations
Study: NCT02224274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study: NCT00367341

Intervention type: DRUG
Group type: OTHER
Intervention: escitalopram
Description: Participants will receive treatment with escitalopram for 12 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT will include 16 1 hour sessions provided over 12 weeks.
Study: NCT05874336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid) is a synthetic small molecule, produced by conjugation of cholic acid (bile acid) and arachidic acid (saturated fatty acid) linked by a stable amide bond.
Study: NCT00774969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 10% ointment three times a day 7 days
Study: NCT00322387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF and plerixafor
Description: G-CSF and plerixafor were administered as described in the treatment arms.
Study: NCT03860662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: botox
Study: NCT01010061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
Study: NCT03735121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
Study: NCT00322387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF and plerixafor
Description: G-CSF and plerixafor were administered as described in the treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF and plerixafor
Description: G-CSF and plerixafor were administered as described in the treatment arms.
Study: NCT03860662

Intervention type: DRUG
Group type: OTHER
Intervention: Baclofen
Description: baclofen
Study: NCT00929890

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General lifestyle, diet and physical activity counselling
Description: Low-calorie, balanced diet and a general advice on the importance of regular physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
Study: NCT03627520

Intervention type: DRUG
Group type: OTHER
Intervention: [14C]Sulfatinib
Description: 300 mg Sulfatinib with 100 µCi \[14C\]
Study: NCT01461564

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Screening colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Screening colonoscopy
Study: NCT03937336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bike Intervention Group
Description: A 1-month biking-based program. The biking program consists of 4 sessions/month of 120 min at physical education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training
Study: NCT02861742

Intervention type: OTHER
Group type: OTHER
Intervention: Delivery of questionnaires
Description: After patient and partner information, clinical research associate or clinical research nurse will give to the couple 2 booklets containing 5 questionnaires, respectively T1, T2, T3, T4 and T5.
Study: NCT03699904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: Participants will self-administer Valaciclovir 1 gram three times daily for 8 weeks.
Study: NCT02861742

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire T1 to fill
Description: T1 is to fill before chemotherapy.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire T2 to fill
Description: T2 is to fill after the 6th cycle of chemotherapy.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire T3 to fill
Description: T3 is to fill at the end of radiotherapy.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire T4 to fill
Description: T4 is to fill 4 month after beginning of hormonotherapy or surveillance if no hormonotherapy.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire T5 to fill
Description: T5 is to fill 1 year after the beginning of hormonotherapy or surveillance if no hormonotherapy.
Study: NCT01375153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNP
Description: 3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: 0.9% NaCl administered as a continuous intravenous infusion during four hours
Study: NCT05944380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 20 mL 0.5% ropivacaine will be injected for the PENG block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,9% normal saline
Description: 20 mL 0.9% normal saline will be injected for the PENG block
Study: NCT00563576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femring®
Description: Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.~Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months.

Intervention type: DRUG
Group type: OTHER
Intervention: DepoProvera ®
Description: Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoProvera ®
Description: Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
Study: NCT03651258

Intervention type: BEHAVIORAL
Intervention: Implementation of ALIJEU
Description: The intervention concerns the passage from the passive feed (gastric tube) to the active feed (breast, feeding bottle).~We propose to set up a pleasant moment just before his meal. This is a practical exercise of a few minutes.~The aim of this special moment is to facilitate child-adult exchanges, improve active food intake and reduce the length of hospital stay.
Study: NCT00399880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health literacy intervention
Description: Illustrated medication schedules, pill boxes, pharmacist counseling
Study: NCT02040779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate breath-actuated inhaler
Description: Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate breath-actuated inhaler
Description: Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
Study: NCT02491203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation system
Description: Usual care plus home-based virtual reality telerehabilitation system.
Study: NCT03699904

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules (containing Avicel blend)
Description: Participants will self-administer two matching placebo capsules (containing Avicel blend) three times daily for 8 weeks.
Study: NCT01978392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management group workshops
Description: This intervention consists of multiple group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months. The intervention incorporates standard elements of existing evidence-based pain and illness self-management efforts, but tailoring key messages and discussion elements to apply to workplace problems most relevant to workers with chronic medical conditions. Each session is focused on different self-management strategies, with each session containing a mix of facilitator presentation, group discussion, case illustrations, role-play, completion of in-session self-assessments and activities, and brief homework assignments. Approximately equal time is allocated to the topics of improving comfort, modifying work, communicating effectively, applying systematic problem-solving strategies, and dealing with negative thoughts and emotions.
Study: NCT01855841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemin
Description: A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
Study: NCT01665976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: film coated tablet, single dose
Study: NCT02040779

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo breath-actuated inhaler
Description: Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
Study: NCT02040779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albuterol/salbutamol
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
Study: NCT00315731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Follicular Lymphoma
Description: For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's
Study: NCT04300894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mamma Mia
Description: Users of the Mamma Mia program progress through the intervention in a sequence of modules.~Every day that a module should be completed, you will receive a notification with a reminder to access the program. By clicking on the reminder, you can access that particular day's session content. Modules involve a variety of information and activities; for example, there are guided mindfulness practices, information on breastfeeding, instructional videos on how to interpret your baby's cries, and discussions on how to have effective discussions with your partner or healthcare provider about your needs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mamma Mia
Description: Users of the Mamma Mia program progress through the intervention in a sequence of modules.~Every day that a module should be completed, you will receive a notification with a reminder to access the program. By clicking on the reminder, you can access that particular day's session content. Modules involve a variety of information and activities; for example, there are guided mindfulness practices, information on breastfeeding, instructional videos on how to interpret your baby's cries, and discussions on how to have effective discussions with your partner or healthcare provider about your needs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mamma Mia Plus
Description: Participants will use the Mamma Mia program, plus receive contact (phone calls or emails or texts) from study staff every few months.
Study: NCT03609723

Intervention type: PROCEDURE
Intervention: CABG
Description: CABG with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC) or CABG without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)

Intervention type: PROCEDURE
Intervention: CABG
Description: CABG with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC) or CABG without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
Study: NCT01451086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine made by Beijing Minhai Biotechnology Co., Ltd
Description: Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: vaccine made by Chengdu Institute of Biological Products
Description: Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
Study: NCT04131777

Intervention type: DEVICE
Intervention: Radiofrequency (RF) catheter
Description: A catheter introduced into the lung lesion via a bronchoscope, used to deliver radiofrequency (RF) energy for the purpose of ablation

Intervention type: DEVICE
Intervention: Radiofrequency (RF) catheter
Description: A catheter introduced into the lung lesion via a bronchoscope, used to deliver radiofrequency (RF) energy for the purpose of ablation
Study: NCT03983824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiogram Recording
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV
Study: NCT01665976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4927838
Description: hard gelatin capsule, single dose
Study: NCT01545414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT
Description: 12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
Study: NCT03983824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO
Study: NCT04443348

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy Boost
Description: Participants randomized to the low-dose or high-dose RT boost group will be receiving treatment on Day 1-3 of Cycle 1 of pembrolizumab. Proton therapy may be used in the high dose RT group.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy Boost
Description: Participants randomized to the low-dose or high-dose RT boost group will be receiving treatment on Day 1-3 of Cycle 1 of pembrolizumab. Proton therapy may be used in the high dose RT group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Neoadjuvant Phase: Day 1 (once every 6 weeks) of Cycles 1-4 (by intravenous infusion) over about 30 minutes.~Adjuvant Phase: Pembrolizumab may be given post-surgery for up to 4 cycles (once every 6 weeks) by intravenous infusion over about 30 minutes. Pembrolizumab after surgery is optional and should be discussed with the study doctor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Neoadjuvant Phase: Day 1 (once every 6 weeks) of Cycles 1-4 (by intravenous infusion) over about 30 minutes.~Adjuvant Phase: Pembrolizumab may be given post-surgery for up to 4 cycles (once every 6 weeks) by intravenous infusion over about 30 minutes. Pembrolizumab after surgery is optional and should be discussed with the study doctor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Neoadjuvant Phase: Day 1 (once every 6 weeks) of Cycles 1-4 (by intravenous infusion) over about 30 minutes.~Adjuvant Phase: Pembrolizumab may be given post-surgery for up to 4 cycles (once every 6 weeks) by intravenous infusion over about 30 minutes. Pembrolizumab after surgery is optional and should be discussed with the study doctor.
Study: NCT02641028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-501
Description: CERC-501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04130997

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
Study: NCT01247909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone v penicillin and gentamicin
Description: Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone v penicillin and gentamicin
Description: Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
Study: NCT00790985

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavocoxid
Description: medical food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: antiinflammatory drug